Income statement
USD
Annual
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 393M | 366M | 341M | 323M | 295M |
| Gross Profit | 0 | 120M | 77M | 96M | 98M |
| Operating Income | 34M | 31M | 14M | 9M | 11M |
| EBITDA | -1M | 83M | 68M | 57M | 61M |
| Net Income | -9M | -14M | -26M | -412K | -23M |
| EPS (Diluted) | — | — | — | — | — |
Real Estate
Live Price
Offline$5.31
+77.00% today
Window Change
+35.85%
Window
Jun 23, 2025 → Feb 18, 2026
Historical coverage is still expanding
This 1Y daily history view is usable, but not fully loaded yet. Additional bars will appear as backfills continue.
Coverage: 81 bars · Jun 23, 2025 → Feb 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
CNL Healthcare Properties, Inc. (CHTH) is a Real Estate stock with a market cap of $930.70M. The stock last traded around $5.31 and up 35.9% across the available one-year price window (Jun 23, 2025 → Feb 18, 2026). Baseline metrics include revenue growth of +7.3%, EPS growth of +39.8%, a dividend yield of 0.0%. What stands out right now is revenue +7.3%, EPS +39.8%, free cash flow +44.3% with operating margin 8.6% and ROIC 47.4%. Valuation is more restrained than many high-expectation growth names at price/sales 2.4. Stock Foundry combines CHTH price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Real Estate peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
CHTH
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
CHTH Max Drawdown
-100.00%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for CHTH and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$295.4M
-8.4% YoY
FY Net Income
-$22.9M
-5447.6% YoY
Free Cash Flow
$32.2M
+23.5% YoY
Revenue Growth
+7.3%
EPS Growth
+39.8%
Gross Margin
0.0%
Net Margin
-2.2%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 393M | 366M | 341M | 323M | 295M |
| Gross Profit | 0 | 120M | 77M | 96M | 98M |
| Operating Income | 34M | 31M | 14M | 9M | 11M |
| EBITDA | -1M | 83M | 68M | 57M | 61M |
| Net Income | -9M | -14M | -26M | -412K | -23M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 56M | 44M | 54M | 70M | 53M |
| Total Assets | 1.3B | 1.3B | 1.4B | 1.4B | 1.4B |
| Total Liabilities | 602M | 608M | 621M | 647M | 626M |
| Shareholder Equity | 686M | 712M | 744M | 790M | 809M |
| Total Debt | 0 | 566M | 578M | 608M | 589M |
| Net Debt | -56M | 522M | 524M | 538M | 536M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
46M
+5.7% YoY
Capital Expenditures
14M
+20.3% YoY
Free Cash Flow
32M
+23.5% YoY
Key ratios
Gross Margin
0.0%
Operating Margin
8.6%
Net Margin
-2.2%
ROE
-1.3%
Debt / Equity
0.00x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.